Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia

Current Hematologic Malignancy Reports

Volumn 4, Issue 3, 2009, Pages 139-147

  Terwey, Theis H ^a   Kim, Theo D ^a   Arnold, Renate ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; IMATINIB;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; REVIEW; WHOLE BODY RADIATION;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK ASSESSMENT; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67650224628     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0020-7     Document Type: Review

References (51)

1. Gokbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46:64-75.
2. Horowitz MM, Messerer D, Hoelzer D, et al.: Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991, 115:13-18.
3. Sebban C, Lepage E, Vernant JP, et al.: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994, 12:2580-2587.
4. Thomas X, Boiron JM, Huguet F, et al.: Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 2004, 22:4075-4086.
5. Hunault M, Harousseau JL, Delain M, et al.: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004, 104:3028-3037.
6. Labar B, Suciu S, Zittoun R, et al.: Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients ≤ 50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica 2004, 89:809-817.
7. Ribera JM, Oriol A, Bethencourt C, et al.: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005, 90:1346-1356.
8. Yanada M, Matsuo K, Suzuki T, Naoe T: Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer 2006, 106:2657-2663.
9. Goldstone AH, Richards SM, Lazarus HM, et al.: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ ECOG E2993). Blood 2008, 111:1827-1833.
10. Cornelissen JJ, van der Holt B, Verhoef GE, et al.: Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison. Blood 2009, 113:1375-1382.
11. Tavernier E, Boiron JM, Huguet F, et al.: Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007, 21:1907-1914.
12. Terwey TH, Massenkeil G, Tamm I, et al.: Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008, 42:791-798.
13. Fielding AK, Richards SM, Chopra R, et al.: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109:944-950.
14. Lee SJ, Klein J, Haagenson M, et al.: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
15. Kiehl MG, Kraut L, Schwerdtfeger R, et al.: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816-2825.
16. Ringdén O, Pavletic SZ, Anasetti C, et al.: The graft-versusleukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009, 113:3110-3118.
17. Mohty M, Labopin M, Tabrizzi R, et al.: Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008, 93:303-306.
18. Dahlke J, Kroger N, Zabelina T, et al.: Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006, 37:155-163.
19. Gratwohl A, Baldomero H, Frauendorfer K, et al.: The EBMT activity survey 2006 on hematopoietic stem cell transplantation: Focus on the use of cord blood products. Bone Marrow Transplant 2008, 41:687-705.
20. Rocha V, Labopin M, Sanz G, et al.: Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
21. Laughlin MJ, Eapen M, Rubinstein P, et al.: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
22. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al.: Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009, 113:1631-1638.
23. Kumar P, Defor TE, Brunstein C, et al.: Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: Impact of donor source on survival. Biol Blood Marrow Transplant 2008, 14:1394-1400.
24. Marks DI, Perez WS, He W, et al.: Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008, 112:426-434.
25. Aversa F: Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: Experience in Europe and the United States. Bone Marrow Transplant 2008, 41:473-481.
26. Ciceri F, Labopin M, Aversa F, et al.: A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: A risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112:3574-3581.
27. Aversa F, Terenzi A, Tabilio A, et al.: Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
28. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al.: Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008, 142:227-237.
29. Bruggemann M, Raff T, Flohr T, et al.: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
30. Raff T, Gokbuget N, Luschen S, et al.: Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109:910-915.
31. Bassan R, Spinelli O, Oldani E, et al.: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
32. Uzunel M, Mattsson J, Jaksch M, et al.: The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001, 98:1982-1984.
33. Spinelli O, Peruta B, Tosi M, et al.: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007, 92:612-618.
34. Sanchez J, Serrano J, Gomez P, et al.: Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002, 116:686-694.
35. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396-4407.
36. Ottmann OG, Wassmann B, Pfeifer H, et al.: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007, 109:2068-2076.
37. Lee S, Kim YJ, Min CK, et al.: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005, 105:3449-3457.
38. Carpenter PA, Snyder DS, Flowers ME, et al.: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
39. Wassmann B, Pfeifer H, Stadler M, et al.: Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, 106:458-463.
40. Stem Cell Trialists' Collaborative Group: Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087.
41. Ringdén O, Labopin M, Bacigalupo A, et al.: Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002, 20:4655-4664.
42. Garderet L, Labopin M, Gorin NC, et al.: Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant 2003, 31:23-29.
43. Marks DI, Forman SJ, Blume KG, et al.: A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006, 12:438-453.
44. Arnold R, Massenkeil G, Bornhauser M, et al.: Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002, 16:2423-2428.
45. Martino R, Giralt S, Caballero MD, et al.: Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003, 88:555-560.
46. Bachanova V, Verneris MR, DeFor T, et al.: Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009, 113:2902-2905.
47. Choi SJ, Lee JH, Lee JH, et al.: Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A prospective study. Bone Marrow Transplant 2005, 36:163-169.
48. Naparstek E, Or R, Nagler A, et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995, 89:506-515.
49. Lutz C, Massenkeil G, Nagy M, et al.: A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:805-812.
50. Attal M, Blaise D, Marit G, et al.: Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995, 86:1619-1628.
51. Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSGALL93 study. Leukemia 2002, 16:1259-1266.